<DOC>
	<DOCNO>NCT01521598</DOCNO>
	<brief_summary>Primary Objective : To evaluate efficacy SKL11197 treatment diabetic peripheral neuropathy pain ( DPN ) . Secondary Objective : To evaluate safety tolerability SKL11197 subject painful diabetic peripheral neuropathy . Primary Efficacy Endpoint : The primary efficacy outcome variable time exit double-blind phase inadequate pain relief .</brief_summary>
	<brief_title>A Phase 2 , Multicenter , Randomized , Double-blind , Placebo Controlled Study Pain Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description>This study double-blind , placebo control study three phase ; 1. pre-study medication washout/screening phase upto 3 week 2. 3-week , open label phase 3. 6-week double-blind phase At end 3-week open label phase , subject may enter double-blind phase meet eligibility criterion . Eligible subject randomize blinded fashion either continue SKL11197 300 mg TID take number placebo capsule .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>1 . 18 year old 2 . Diagnosis Type 1 Type 2 diabetes mellitus least 1 year 3 . At least moderate pain , â‰¥ 40mm 100mm VAS end washout phase ( absence analgesic ) ; 4 . HbA1c &lt; 12 % Screening 5 . Daily pain attribute diabetic neuropathy least 3 month prior Screening basis history physical examination document peripheral neuropathy . 6 . Pain diabetic neuropathy identifiable subject . Pain must involve low extremity bilateral . 7 . Females must nonchildbearing potential ( define either surgically sterile least one year postmenopausal , Menopause define 1 year since last menstrual period associate subjective sensation ) , , 8 . If capable bearing child , female must use doublebarrier method contraception , intrauterine device . Females capable bearing child must negative serum pregnancy ( betaHCG ) test Screening negative urine pregnancy Day 1 . 1 . Pregnant lactating female 2 . Subjects BMI 40 3 . Pain due symptomatic peripheral vascular disease ( e.g . intermittent claudication ) 4 . Subjects know clinically significant decrease blood flow extremities 5 . Subjects pain source confuse assessment diabetic neuropathic pain 6 . Peripheral neuropathy attributable cause alcoholism , connective tissue disease , toxic exposure ; 7 . Have profound autonomic dysfunction , brittle diabetes ; 8 . Evidence amputation ( include toe ) , open ulcer , Charcot joint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Diabetic Peripheral Neuropathy</keyword>
</DOC>